Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VERTIS SU
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 31 Mar 2020 Results of post hoc analysis of two randomised controlled trials (NCT01999218 [VERTIS SU] and NCT02033889 [VERTIS MET) published in the Diabetologia
- 06 Dec 2019 Results (n=335) of pooled analysis from VERTIS MET, VERTIS SITA2 and VERTIS SU comapring efficacy of ertugliflozin between patients from East Asian and non-East Asian sites, presented at the 2019 Congress of the International Diabetes Federation
- 11 Jun 2019 Results of post hoc analysis of Ertugliflozin efficacy and safety in Hispanic/Latino patients in the Ertugliflozin Phase 3 trials (NCT01958671, NCT02033889, NCT02036515, NCT01999218, NCT02226003, NCT02099110, NCT01986855) presented at the 79th Annual Scientific Sessions of the American Diabetes Association.